Medicenna Therapeutics Corp faced a notable decline in its stock price, reflecting investor concerns.
In yesterday's trading session, Medicenna Therapeutics Corp (MDNA.TO) saw its stock price drop by 4.76%, closing at CA$0.40. This decline raises questions about the company's recent performance and future prospects.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$36.92M
52W high
$1.97
52W low
$0.34
1W change
-13.04%
Beta
1.96
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 700.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+700.0% Upside
Current Price
C$0.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
67.3%
Annualized
90-Day Vol
65.8%
Annualized
Trend (90d)
-30.4%
Annualized drift
90d Mean
C$0.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.39 | C$0.31 – C$0.49 |
| 60 trading days | C$0.37 | C$0.27 – C$0.52 |
| 90 trading days | C$0.36 | C$0.24 – C$0.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The drop in Medicenna's stock price highlights the volatility that can occur in the biotech sector, particularly when companies are navigating funding and regulatory challenges.
Medicenna's stock fell by 4.76% yesterday.
The market capitalization of Medicenna is now approximately CA$36.9 million, reflecting investor sentiment amid ongoing challenges.
Bull case
Investors might see potential in Medicenna's ongoing development of innovative therapies, especially with positive data coming from recent presentations. These advancements could lead to new opportunities for growth and recovery in the stock price.
Bear case
The recent decline in stock price raises concerns about the company's financial health and market positioning. With a lack of recent positive news, investors may worry about Medicenna's ability to navigate its current challenges and achieve future success.
Stock Performance Overview
Advertisement
Yesterday, Medicenna's stock fell by 4.76%, closing at CA$0.40. This decline is a stark reminder of the volatility that can characterize biotech stocks, especially in light of recent funding activities. The company's market cap now stands at approximately CA$36.9 million, which may raise concerns among investors about its financial stability.
Investor Sentiment and Market Reaction
The drop in Medicenna's stock price could reflect broader investor sentiment regarding the biotech sector's challenges. Despite the company's recent announcement of a public offering that raised approximately CDN$4.44 million, the market's reaction suggests that investors are cautious about the company's future growth and operational viability. For more insights on Medicenna's performance, check out our detailed analysis on MDNA.TO.
Looking Ahead
As Medicenna continues to develop its innovative therapies, investors will be watching closely for any updates that could influence stock performance. The recent presentation of positive data on MDNA113 at industry conferences may provide some optimism, but the market's response indicates that many remain skeptical. For ongoing updates and analysis, stay tuned to our coverage on Medicenna Therapeutics Corp.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
